Milot A, Lambert R, Lebel M, Cusson J R, Larochelle P
Centre de recherche, Hôpital St. Françoise d'Assise, Québec, Canada.
J Hypertens. 1996 Jun;14(6):765-71. doi: 10.1097/00004872-199606000-00013.
This study was designed to compare the effects of prostaglandin synthesis inhibition on calculated preglomerular and postglomerular resistance in hypertensive patients with unilateral renal artery stenosis (RAS) and in patients with essential hypertension.
Sixteen patients with suspected renovascular hypertension underwent renal angiography: eight had unilateral renal artery stenosis > or = 70% and eight had normal angiograms or stenosis < or = 40%. Radionuclide renography and 6 h urinary collection were performed twice for each subject, at baseline and after indomethacin administration. Levels of urinary vasodilatory prostaglandins were measured by specific radioimmunoassays. Visual image analysis was performed to determine the parenchymal transit time (PTT). The glomerular filtration rate (GFR) was calculated from the plasma clearance of [99mTc]-diethylenetriamine pentaacetic acid (DTPA). The preglomerular and postglomerular resistances were estimated according to Gomez's equations.
The prostaglandin excretion decreased significantly after indomethacin administration both in RAS and in essential hypertension patients. The PTT increased from 230 +/- 10 to 340 +/- 40s in the stenotic kidney compared with the contralateral kidney and the kidneys of essential hypertension patients. The GFR was decreased both in stenotic and in contralateral kidneys (48 +/- 4 to 37 +/- 5 and 60 +/- 4 to 52 +/- 5 ml/min, respectively) but did not decline in the kidneys of essential hypertension patients. The preglomerular resistance increased both in stenotic and in contralateral kidneys, whereas it did not rise significantly in the kidneys of essential hypertension patients. The postglomerular resistance in stenotic and contralateral kidneys of RAS patients was not altered.
Prostaglandins limit GFR decreases in RAS by preventing preglomerular constriction without interfering with postglomerular constriction. Thus, the action of vasoactive prostaglandins on preglomerular resistance might maintain renal function in the short term by limiting the fall in GFR in the stenotic kidney and by increasing the GFR in the contralateral kidney.
本研究旨在比较前列腺素合成抑制对单侧肾动脉狭窄(RAS)高血压患者和原发性高血压患者计算得出的肾前和肾后阻力的影响。
16例疑似肾血管性高血压患者接受了肾血管造影:8例单侧肾动脉狭窄≥70%,8例血管造影正常或狭窄≤40%。对每位受试者在基线和服用吲哚美辛后进行两次放射性核素肾图检查和6小时尿液收集。通过特定放射免疫分析法测量尿中血管舒张性前列腺素水平。进行视觉图像分析以确定实质转运时间(PTT)。根据戈麦斯方程计算肾小球滤过率(GFR)。根据戈麦斯方程估算肾前和肾后阻力。
服用吲哚美辛后,RAS患者和原发性高血压患者的前列腺素排泄均显著降低。与对侧肾脏和原发性高血压患者的肾脏相比,狭窄肾脏的PTT从230±10秒增加到340±40秒。狭窄肾脏和对侧肾脏的GFR均降低(分别从48±4降至37±5和从60±4降至52±5 ml/分钟),但原发性高血压患者的肾脏GFR未下降。肾前阻力在狭窄肾脏和对侧肾脏中均增加,而在原发性高血压患者的肾脏中未显著升高。RAS患者狭窄肾脏和对侧肾脏的肾后阻力未改变。
前列腺素通过防止肾前收缩而不干扰肾后收缩来限制RAS患者GFR的降低。因此,血管活性前列腺素对肾前阻力的作用可能通过限制狭窄肾脏GFR的下降和增加对侧肾脏GFR在短期内维持肾功能。